SOH approves the HTAC recommendation on tocilizumab for COVID-19 in the Philippine National Formulary (PNF) The Secretary of Health (SOH) approved the HTAC recommendation on the addition of tocilizumab for COVID-19 in the Philippine National Formulary (PNF) on 11 May 2022. On 15 March 2022, the Philippine FDA issued the CPR of tocilizumab for the treatment of continue reading : Tocilizumab for the Treatment of COVID-19
Potassium Citrate [1620 mg (15 mEq)] Tablet
SOH approves the HTAC recommendation on the minor inclusion of an additional dosage strength of potassium citrate [1620 mg (15mEq)] tablet for severe hypocitraturia and recurrent kidney stones in the Philippine National Formulary (PNF) The Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation on the minor inclusion of an additional dosage continue reading : Potassium Citrate [1620 mg (15 mEq)] Tablet
Vasopressin 20 I.U./mL (I.V./I.M./S.C.)
The Secretary of Health (SOH) approved the HTAC recommendation on the reinclusion of vasopressin in the PNF on 02 March 2022. Link to issuance Vasopressin 20 I.U./mL (I.V./I.M./S.C.) was previously listed in the Philippine National Formulary (PNF); however, it was automatically delisted in 2017 since the drug was no longer registered in the Philippine Food continue reading : Vasopressin 20 I.U./mL (I.V./I.M./S.C.)
Use of Casirivimab + Imdevimab for the Treatment of COVID-19
HTAC interim recommendation on the use of casirivimab+imdevimab for the treatment of COVID-19 On 24 December 2021, the Secretary of Health approved and signed the Health Technology Assessment Council (HTAC) interim recommendation for the government not to finance casirivimab+imdevimab for the treatment of COVID-19. The Philippine Food and Drug Administration (FDA) issued an Emergency Use Authorization continue reading : Use of Casirivimab + Imdevimab for the Treatment of COVID-19